# US 2026/0085301 A1 · Compositions and methods for modifying genomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085301 A1
- Document ID: US20260085301A1
- Status: Published application
- Kind: A1
- Application number: 19/334,505
- Filed: 2025-09-19
- Published: 2026-03-26
- Earliest claimed: 2024-09-20
- Assignees: Confluence Genetics, LLC
- Applicants: Confluence Genetics, LLC
- Inventors: Matthew Brett Begemann; Emma Elizabeth January; Gina C. Neumann; Allison Jane Newton Antonakos; Anna Singer; Erin Zess
- Web page: https://patentgrep.com/patent/US20260085301A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8213: {Targeted insertion of genes into the plant genome by homologous recombination}
- C12N 15/86: Viral vectors
- C12N 15/902: {using homologous recombination}
- C12N 15/907: {in mammalian cells}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions and methods for targeting pre-determined DNA sequences in cells of interest are provided. The methods result in the targeted elimination of cells that comprise the pre-determined DNA sequence(s). Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cas12a2 protein operably linked to a promoter that is operable in the cells of interest. Methods to use these DNA constructs to selectively target and eliminate cells that harbor the targeted DNA sequence(s) are described herein.

## Claims

### Claim 1

A composition comprising a Cas12a2 polypeptide or a polynucleotide encoding the Cas12a2 polypeptide, wherein the Cas12a2 polypeptide shares at least 85% identity with a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55, or wherein the Cas12a2 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55.

### Claim 2 (depends on 1)

The composition of any one of claim 1, wherein said Cas12a2 polypeptide comprises one or more amino acid motifs (i) having at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 32, 40, 42, 30, 31, 33-39, 41, and 43-46, or (ii) selected from the group consisting of SEQ ID NOs: 32, 40, 42, 30, 31, 33-39, 41, and 43-46.

### Claim 3 (depends on 1)

A composition comprising:
(i) the Cas12a2 polypeptide or a polynucleotide encoding the Cas12a2 polypeptide of claim 1, and
(ii) a guide polynucleotide, or a polynucleotide encoding a guide polynucleotide, wherein said guide polynucleotide is designed to bind said Cas12a2 polypeptide and hybridize with a target sequence in one or more cells of interest, wherein said target sequence is located adjacent to a protospacer adjacent motif (PAM) sequence or a protospacer flanking motif (PFM) sequence that is recognized by said Cas12a2 polypeptide.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said one or more cells of interest are cells of one or more pests of interest, and the target sequence is a target sequence specific to the one or more pests of interest.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said one or more pest of interest is a pathogenic bacterial species.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said pathogenic bacterial species is associated with plants, mammals, or humans.

### Claim 7 (depends on 3)

The composition of claim 3, wherein said one or more cells of interest are one or more eukaryotic cells.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said one or more eukaryotic cells are one or more cells of at least one plant pathogen, and wherein the target sequence is a target sequence specific to said one or more plant pathogens.

### Claim 9 (depends on 8)

The composition of claim 8, wherein said at least one plant pathogen is a plant parasitic nematode, an insect, a fungus, a virus, a mollusk, a spider, a scorpion, a caterpillar, an animal, a mite, a tick, or a combination thereof.

### Claim 10 (depends on 7)

The composition of claim 7, wherein said one or more eukaryotic cells are one or more mammalian cells or human cells.

### Claim 11 (depends on 10)

The composition of claim 10, wherein said one or more mammalian cells or human cells are one or more cancer cells, and wherein said target sequence is a cancer cell-specific target sequence.

### Claim 12 (depends on 3)

The composition of claim 3, wherein said guide polynucleotide is a guide RNA.

### Claim 13 (depends on 3)

The composition of claim 3, wherein said PAM sequence comprises TTNV, VTTV, or TCTV, wherein N is A, G, C, or T, and wherein V is A, G, or C.

### Claim 14 (depends on 3)

The composition of claim 3, wherein the guide polynucleotide comprises a spacer comprising a nucleic acid sequence differing by no more than 4 nucleotides from a nucleic acid sequence fully complementary to the target sequence.

### Claim 15 (depends on 1)

A vector comprising the polynucleotide encoding a Cas12a2 polypeptide of claim 1.

### Claim 16 (depends on 15)

The vector of claim 15, wherein said vector is selected from the group consisting of phages, phagemids, and conjugative plasmids.

### Claim 17 (depends on 16)

The vector of claim 16, wherein said phage or phagemid is derived from a phage selected from the group consisting of M13, lambda, p22, T7, Mu, T4 phage, PBSX, P1Puna-like, P2, 13, Bcep 1, Bcep 43, Bcep 78, T5 phage, phi, C2, L5, HK97, N15, T3 phage, P37, MS2, Q.beta., or Phi X 174, T2 phage, T12 phage, R17 phage, M13 phage, G4 phage, Enterobacteria phage P2, P4 phage, N4 phage, Pseudomonas phage .PHI.6, .PHI.29 phage and 186 phage.

### Claim 18 (depends on 16)

The vector of claim 16, wherein said vector is a viral vector.

### Claim 19 (depends on 18)

The vector of claim 18, wherein the viral vector is an adeno-associated virus (AAV) vector.

### Claim 20 (depends on 16)

The vector of claim 16, wherein said polynucleotide encoding the Cas12a2 polypeptide and a polynucleotide encoding a guide polynucleotide are part of the same polynucleotide.

### Claim 21

A method for binding, cleaving, and/or modifying a target sequence in one or more cells of interest comprising delivering to said one or more cells
(a) a composition comprising:
(i) a Cas12a2 polypeptide or a polynucleotide encoding the Cas12a2 polypeptide, wherein the Cas12a2 polypeptide shares at least 85% identity with a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55, or wherein the Cas12a2 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55; and
(ii) a guide polynucleotide, or a polynucleotide encoding a guide polynucleotide, wherein said guide polynucleotide is designed to bind said Cas12a2 polypeptide and hybridize with a target sequence in one or more cells of interest, wherein said target sequence is located adjacent to a protospacer adjacent motif (PAM) sequence or a protospacer flanking motif (PFM) sequence that is recognized by said Cas12a2 polypeptide, or
(b) a vector comprising the composition, thereby binding, cleaving, and/or modifying said target sequence with the Cas12a2 polypeptide of the composition.

### Claim 22 (depends on 21)

The method of claim 21, wherein the one or more cells of interest is one or more bacterial cells or eukaryotic cells.

### Claim 23 (depends on 22)

The method of claim 22, wherein said one or more eukaryotic cells belongs to one or more plant pathogens.

### Claim 24 (depends on 23)

The method of claim 23, wherein said one or more plant pathogens is a plant parasitic nematode, an insect, a fungus, a virus, a mollusk, a spider, a scorpion, a caterpillar, an animal, a mite, a tick, or a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein said one or more eukaryotic cells is one or more mammalian cells, human cells, or cancer cells.

### Claim 26 (depends on 21)

The method of claim 21, wherein delivering comprises delivering said one or more cells with a phage or a phagemid engineered to comprise:
(i) a polynucleotide encoding said Cas12a2 polypeptide, and
(ii) a polynucleotide encoding a guide polynucleotide.

### Claim 27 (depends on 21)

The method of claim 21, wherein delivering comprises delivering said one or more cells with a viral vector engineered to comprise:
(i) a polynucleotide encoding said Cas12a2 polypeptide, and
(ii) a polynucleotide encoding a guide polynucleotide.

### Claim 28 (depends on 27)

The method of claim 27, wherein the viral vector is an adeno-associated virus (AAV) vector.

### Claim 29 (depends on 21)

A modified cell produced by the method of claim 21.

### Claim 30

A cell, a plant, a plant part, or a plant pathogen comprising a composition comprising a Cas12a2 polypeptide or a polynucleotide encoding the Cas12a2 polypeptide, wherein the Cas12a2 polypeptide shares at least 85% identity with a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55, or wherein the Cas12a2 polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 1, 2, 4-14, and 55.
